Ipamorelin vs CJC-1295

Overview

This comparison separates Ipamorelin and CJC-1295 for reference—not product selection.

Ipamorelin: Selective growth hormone secretagogue studied for stimulating growth hormone with little effect on cortisol.

CJC-1295: Short-acting growth hormone-releasing hormone analogue studied in growth hormone research.

Differences

• Ipamorelin is discussed in relation to ghrelin receptor; CJC-1295 is discussed in relation to GHRH receptor.
• Both appear in Growth hormone & endocrine research literature, but mechanistic framing differs.

Mechanism

Ipamorelin: Rather than supplying growth hormone directly, ipamorelin prompts the pituitary to release its own. This preserves the body's natural pulsed release pattern and…

CJC-1295: Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows…

Pharmacology

Ipamorelin: Pharmacokinetic detail should be read from primary literature.

CJC-1295: Pharmacokinetic detail should be read from primary literature.

Research

Ipamorelin: Growth hormone & endocrine research: Consistent GH elevation 30-60 minutes post-injection, maintaining natural pulsatile patterns.

CJC-1295: Growth hormone & endocrine research: Restores natural GH pulsatility patterns in aging individuals.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/9849822/
• pubmed.ncbi.nlm.nih.gov/25331030/
• pubmed.ncbi.nlm.nih.gov/10496658/
• pubmed.ncbi.nlm.nih.gov/10373343/
• pubmed.ncbi.nlm.nih.gov/11735244/
• pubmed.ncbi.nlm.nih.gov/16352683/
• pubmed.ncbi.nlm.nih.gov/17018654/
• pubmed.ncbi.nlm.nih.gov/15817669/

Questions